TERN — Terns Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1831363 ·
Last close
$52.95
Market Cap
$6.12B
52W High
$53.19
52W Low
$38.82
ADV30
6,660,975
Next earnings
2026-05-07
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -27,598,000 | -23,571,000 | 1,025,078,000 | 524,747,000 | 18,554,000 |
| Sep 2025 | 0 | — | -27,716,000 | -24,635,000 | 301,651,000 | 150,698,000 | 17,585,000 |
| Jun 2025 | 0 | — | -27,383,000 | -24,093,000 | 320,415,000 | 145,966,000 | 15,186,000 |
| Mar 2025 | 0 | — | -27,427,000 | -23,908,000 | 339,315,000 | 139,023,000 | 13,272,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-82,176,000
Investing CF
$-298,043,000
Financing CF
$743,511,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.03
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-517,688,000
Inventory
—
Receivables
—
ST Investments
$494,235,000
EBIT TTM
$-110,124,000
Pretax Income TTM
$-95,626,000
Interest Exp TTM
—
Analysts
4
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -110,124,000 | -96,207,000 | 1,025,078,000 | 18,554,000 | — | -82,176,000 |
| Dec 2024 | 0 | -101,871,000 | -88,853,000 | 363,929,000 | 18,059,000 | — | -70,016,000 |
| Dec 2023 | 0 | -102,558,000 | -90,210,000 | 268,517,000 | 13,150,000 | — | -67,390,000 |
| Dec 2022 | 0 | -62,029,000 | -60,345,000 | 287,026,000 | 10,083,000 | — | -49,109,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.56
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TGTX | TG THERAPEUTICS, INC. | $6.08B | $39.73 | — |
| CNTA | Centessa Pharmaceuticals plc | $6.16B | $39.78 | — |
| RYTM | RHYTHM PHARMACEUTICALS, INC. | $6.16B | $89.82 | — |
| MIRM | Mirum Pharmaceuticals, Inc. | $6.03B | $98.90 | — |
| ALKS | Alkermes plc. | $6.23B | $37.35 | — |
News headlines (Yahoo Finance, 1h cache)
Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy
2026-05-16 15:01 · Yahoo
MSD concludes Terns acquisition to expand CML pipeline
2026-05-06 09:47 · Yahoo
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.
2026-05-05 12:45 · Yahoo
Merck still sees ‘compelling’ outlook for Terns leukemia drug
2026-04-30 12:21 · Yahoo
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia
2026-04-27 12:05 · Yahoo
Merck Advances Terns Deal And Cardiovascular And RSV Growth Options
2026-04-26 23:06 · Yahoo
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.
2026-04-24 10:45 · Yahoo
UBS Raises Merck (MRK) Price Forecast as Part of Sector Preview
2026-04-17 17:54 · Yahoo
AZN vs. MRK: Which Oncology Stock Offers Better Investment Potential?
2026-04-09 13:18 · Yahoo
Why Terns Pharmaceuticals Stock Rocked the Market in March
2026-04-08 18:20 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.